S&P 500 Technology Sector SEC Filings — June 01, 2026

01-06-2026

MoonLake Immunotherapeutics entered into a Master Commercial Supply Agreement and a Capacity Agreement with Vetter Pharma International GmbH on May 22, 2026, for manufacturing of pre-filled application systems. The agreements include binding capacity commitments with minimum and maximum quantities, and potential compensation obligations if MoonLake fails to meet commitments. No financial terms were disclosed.

• · The Vetter MCSA is a master agreement under which product-specific schedules will detail manufacturing services and pricing.
• · Either party may terminate the Vetter MCSA without cause upon 12 months' written notice.
• · Vetter may terminate if MoonLake undergoes a Change of Control to an acquirer not meeting specified criteria; MoonLake may terminate if Vetter is taken over by a competitor in dermatology/inflammatory diseases before end of 2029.
• · The Capacity Agreement requires MoonLake to provide aggregate demand forecasts, with annual demands for the initial term constituting a binding commitment (MoonLake Commitment).
• · MoonLake may be obligated to pay capacity compensation if it fails to order the Minimum Quantity or fails to provide purchase orders.

01-06-2026

Diana Shipping Inc. filed an amended Schedule 13D/A disclosing its tender offer to acquire all outstanding shares of Genco Shipping & Trading Ltd at $24.80 per share, now beneficially owning 6,264,548 shares (14.4% of class). The filing includes an open letter and video message urging Genco shareholders to elect Diana’s six independent director nominees at the June 18, 2026 annual meeting, while criticizing the Genco board for spending over $13 million on defensive advisors and failing to engage on the offer. However, the tender offer has not yet been accepted by the board, and Diana notes that Genco’s share price could revert to ~$18.00 (a ~30% discount to NAV) if no deal is completed.

• · Diana's offer represents ~1.0x NAV at cyclically high asset values, while comparable industry buyouts trade at ~0.80x NAV.
• · Genco had 43,577,051 common shares outstanding as of May 6, 2026.
• · The tender offer expires at 5:00 p.m. New York City time on June 26, 2026.
• · Genco's annual meeting is scheduled for June 18, 2026.
• · Diana has increased its offer three times (third proposal at $24.80).
• · John Wobensmith serves as both Chairman and CEO after adding the Chairman role in August 2025 as Diana was acquiring Genco shares.
• · A majority of Wobensmith's Genco stock was pledged as collateral for personal loans (since repaid).
• · Kathleen Haines was named co-defendant in three shareholder class action lawsuits alleging lack of independence while serving on the OSG America board.

01-06-2026

Weatherford International plc announced a definitive agreement to acquire NCS Multistage Holdings, Inc., expected to close in H2 2026. The acquisition aims to expand Weatherford's well completions and unconventional reservoir capabilities. No financial terms were disclosed.

• · Transaction expected to close in second half of 2026, subject to regulatory approvals.
• · Pre-integration team established under Manoj Nimbalkar.
• · Employees instructed not to alter pricing or engage customers on combined capabilities until close.
• · Weatherford and NCS Multistage will operate independently until close.

01-06-2026

Community Financial System, Inc. (CBU) announced the completion of its acquisition of ClearPoint Federal Bank & Trust by its subsidiary Community Bank, N.A. on June 1, 2026. ClearPoint is a national leader in trust administration for the death care industry with over $1.5 billion in assets under management and a historical three-year revenue CAGR of 9.7%. The transaction expands the wealth management services of Nottingham Financial Group and aligns with the company's strategic focus on durable, recurring income streams.

• · The acquisition was completed on June 1, 2026, as previously announced in an Agreement and Plan of Merger dated January 14, 2026.
• · The newly acquired business will operate as ClearPoint Trust, a division of Community Bank.
• · The press release announcing the closing is attached as Exhibit 99.1 to the 8-K filing.

01-06-2026

Sun Communities, Inc. (SUI) filed an 8-K on June 1, 2026, to furnish an investor presentation that will be made available to investors and posted on its website. The filing also discloses forward-looking risks related to the proposed sale of Park Holidays, including the ability to complete the sale on a timely basis, potential disruptions to operations, and the realization of anticipated benefits.

• · The investor presentation is furnished under Item 7.01 Regulation FD Disclosure and is not deemed 'filed' for SEC purposes.
• · The filing includes extensive forward-looking statements and risk factors, notably around the proposed sale of Park Holidays, liquidity, refinancing, interest rates, and macroeconomic conditions.
• · The presentation will be posted on Sun Communities' website at www.suninc.com/investor-relations.

01-06-2026

Community Health Systems Inc. completed the sale of four Arkansas hospitals and associated outpatient centers to Freeman-Oak Hill Health System for $110 million in cash on June 1, 2026. The transaction resulted in a pro forma net loss on sale of $48 million after tax, and the company recorded a $55 million pre-tax loss. Pro forma adjustments show the divested facilities contributed approximately $111 million in net operating revenues for Q1 2026 and $415 million for FY 2025, representing about 3.7% and 3.3% of total revenues, respectively.

• · The divested facilities' operations do not meet the definition of discontinued operations under ASC 205.
• · Pro forma adjustments exclude certain general corporate overhead costs previously allocated to the Facilities that will continue post-closing.
• · The pro forma net loss on sale of $48 million is after a $7 million income tax benefit.
• · For FY 2025, pro forma net income attributable to CHS stockholders decreased from $509 million to $472 million, and diluted EPS decreased from $3.77 to $3.50.
• · For Q1 2026, pro forma net loss attributable to CHS stockholders remained unchanged at $58 million, and diluted EPS remained at $(0.43).
• · The company's total assets decreased by $115 million on a pro forma basis, from $13,180 million to $13,065 million as of March 31, 2026.
• · Stockholders' deficit increased by $48 million on a pro forma basis, from $1,225 million to $1,273 million.

01-06-2026

Salesforce held its 2026 Annual Meeting on May 28, 2026, where all 13 director nominees were elected, and stockholders approved amendments to the 2013 Equity Incentive Plan (adding 34 million shares) and the 2004 Employee Stock Purchase Plan. The advisory vote on executive compensation passed with 79.5% support, while a shareholder proposal on cumulative voting was overwhelmingly rejected. Notably, several directors received significant against votes, including John V. Roos (6.6% against), Mason Morfit (5.8% against), and Robin Washington (5.9% against).

• · Directors with highest against votes: John V. Roos (40,064,925 against), Mason Morfit (35,106,845 against), Robin Washington (36,317,035 against).
• · Ratification of Ernst & Young as auditor passed with 663,734,521 for, 49,972,013 against.
• · Amendment to 2004 Employee Stock Purchase Plan passed with 609,941,606 for, 1,918,316 against.
• · Broker non-votes were 102,463,325 for all director elections and most proposals except auditor ratification.

01-06-2026

BlockchAIn Digital Infrastructure, Inc. (AIB) announced a 15-year Electric Service Agreement (ESA) to expand its contracted utility load at the CLT-01 data center campus from 40 MW to 65 MW, with the full 65 MW immediately available through existing 34.5 kV infrastructure requiring no significant electrical upgrades. The expanded capacity supports a growing customer pipeline including letters of intent for 25 MW of committed critical IT load from a leading AI company and a financial institution. However, the remaining phase of infrastructure expansion (a new AI-optimized data center shell) is expected to take up to nine months to complete, and the company faces execution risks including permitting delays, contractor performance, and the ability to convert letters of intent into definitive contracts.

• · The expanded power load represents the first phase of the site's broader infrastructure expansion; the second phase (new data center shell) is expected to be completed in nine months.
• · Christopher Iannacone, former Director of Project Management at Amazon with 25+ years of experience overseeing 3+ gigawatts of data center capacity, will lead project execution.
• · The company's business development team includes Eyal Rozen (former Nebius executive) and Gary Heitz (former Google and Dell business development leader).
• · The press release contains forward-looking statements and cautions that actual results may differ materially due to risks including utility counterparty performance, permitting delays, tariff changes, and market conditions.

01-06-2026

Immuneering Corp announced updated Phase 2a data for atebimetinib in combination with mGnP in first-line pancreatic cancer, showing a median overall survival of 17.3 months in 55 patients (320 mg ITT population) versus 8.5 months for standard of care, with a median follow-up of 11.6 months. The drug was generally well tolerated, with Grade ≥3 adverse events including anemia (16%) and neutropenia (18%), and no Grade 5 events. However, the data are from a non-randomized trial without head-to-head comparison, and the company expects to start a pivotal Phase 3 trial in mid-2026 with topline data in mid-2028.

• · Median follow-up time was 11.6 months as of the cutoff date.
• · Grade ≥3 TEAEs in <10% of patients included Rash (5%), Fatigue (2%), Vomiting (2%), and Oedema Peripheral (2%).
• · No Grade 5 TEAEs were observed and no new safety signals were identified.
• · First patient in pivotal Phase 3 trial (MAPKeeper 301) expected in mid-2026 with topline data in mid-2028.
• · First patient in atebimetinib + Libtayo trial for NSCLC expected in H2 2026 with preliminary data in late-2027.
• · Additional preclinical data for atebimetinib + anti-PD-1 in NSCLC expected in Q4 2026.
• · IND-enabling studies for next Deep Cyclic Inhibition candidate expected to begin in mid-2027.

01-06-2026

Optimum Communications (OPTU) has launched a major capital structure repositioning by forming a new unrestricted subsidiary (Unsub Topco) to hold its Optimum East Cable business and 50.01% stake in Lightpath, insulating these assets from the $21.8 billion debt burden at its subsidiary CSC Holdings, of which $6.2 billion matures in 2027. The new subsidiary raised $500M through a $300M private placement of preferred units to institutional investors and a $200M exchange of preferred units for Optimum stock held by controlling stockholder Next Alt S.à r.l. at $2.50/share. Concurrently, a cash tender offer for up to $300M of Optimum common stock at $2.50/share has commenced. While these transactions aim to protect stakeholder value and facilitate consensual debt restructuring negotiations, the company faces a potential multi-billion-dollar tax liability exceeding $4 billion if a restructuring triggers a deconsolidation event, and the CSC Holdings debt maturity cliff in 2027 presents significant refinancing risk.

• · Co-Op Group holds approximately 99% of CSC Holdings Debt and has a Cooperation Agreement that prevents individual restructuring deals, severely limiting traditional refinancing options.
• · Unsub Topco structure was implemented in compliance with existing CSC Holdings debt documents and does not impact day-to-day operations, employees, management team, or board composition.
• · If significantly fewer shares are tendered than the $300M maximum, Unsub Topco plans to conduct a registered public exchange offering preferred units on similar economic terms.
• · Optimum is not a guarantor or obligor under CSC Holdings Debt — it is a holding company.
• · Advisors: Evercore (placement agent), Altman Solon LP (industry consultant), White & Case and Quinn Emanuel (legal counsel).

01-06-2026

Aditxt, Inc. (ADTX) appointed Jeffrey M. Busch as Interim CEO effective May 31, 2026, replacing founder Amro Albanna who resigned as CEO and board member. Mr. Busch previously founded a NYSE-listed healthcare REIT (Global Medical REIT/GMRE) that he built to over $1 billion in enterprise value while delivering ~8.5% average dividend yield to shareholders. The company plans to accelerate commercialization of its Ignite Proteomics precision oncology diagnostics platform under the new leadership. While the press release is optimistic about Busch's background and the strategic priorities, the filing does not disclose any financial figures for Aditxt itself, nor does it address the company's current liquidity, revenue trajectory, or going concern risks — significant uncertainties typical for a small-cap life sciences company with no disclosed dividend policy and a volatile stock (Nasdaq: ADTX).

• · Aditxt does not currently have a dividend policy and has no current plan or intention to declare cash dividends — the 8.5% dividend yield reference relates solely to Busch's prior role at GMRE, not Aditxt.
• · Busch has served as CEO of Ignite Proteomics since March 2026 and will continue both roles.
• · The outgoing CEO Amro Albanna resigned as CEO, from the board, and from all subsidiary positions — he co-founded Aditxt and led the company through its public listing and acquisition strategy.
• · Aditxt's strategic priorities under new leadership are: patients first, revenue-driven innovation, stakeholder responsibility, and capital market engagement.
• · Ignite Proteomics holds a Medicare PLA code for its RPPA-based precision oncology tests and has clinical collaborations with Dana-Farber Cancer Institute and Vanderbilt University Medical Center.
• · The press release provides no current financial data for Aditxt (no revenue, cash balance, debt, or operating metrics).

01-06-2026

Dime Community Bancshares, Inc. filed a Certificate of Amendment to change its corporate name to 'Dime Commercial Bancshares, Inc.' The amendment was authorized by the board of directors and a majority shareholder vote. The name change reflects a strategic shift from a community banking focus to a commercial banking identity.

• · The original incorporation date was September 13, 1998.
• · The company was originally formed as Bridge Bancorp, Inc.
• · The amendment was filed under Section 805 of the New York Business Corporation Law.
• · The filing fee for the certificate was $60.

01-06-2026

On June 1, 2026, PSQ Holdings, Inc. filed an 8-K disclosing the departure of officer Michael Hebert, effective May 26, 2026, pursuant to a Severance Agreement and General Release. The filing includes the severance agreement as Exhibit 10.1 and a cover page interactive data file. No financial impact or replacement officer is detailed in this filing.

• · The severance agreement was entered into effective May 26, 2026.
• · Exhibit 10.1 is the Severance Agreement and General Release with Michael Hebert.
• · Exhibit 104 is the Cover Page Interactive Data File embedded in Inline XBRL.
• · No replacement officer or further succession details are mentioned in the filing.